Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cobicistat + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- German Cancer Research Center
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of the CYP3A inhibitor cobicistat, the nucleoside analog gemcitabine, and the microtubule inhibitor nab-paclitaxel (nanoparticle albumin-bound paclitaxel). Developed by the German Cancer Research Center (DKFZ), this regimen is being investigated in the Phase I IntenSify trial for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The rationale for this combination is to use cobicistat to inhibit CYP3A-mediated metabolism and potential resistance mechanisms, thereby enhancing the pharmacokinetic profile and therapeutic efficacy of the standard-of-care chemotherapy backbone (gemcitabine and nab-paclitaxel). Gemcitabine acts as an antimetabolite that inhibits DNA synthesis, while nab-paclitaxel promotes microtubule assembly and stabilization, leading to cell cycle arrest and apoptosis.
- Other names
- gemcitabine + nab-paclitaxel + cobicistatIntenSify regimen
02
Targets
CDA (Cytidine deaminase)RNR (Ribonucleotide reductase)CYP3A7 (Cytochrome P450 3A7)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cobicistat + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cobicistat + gemcitabine + nab-paclitaxel.